Newsmeme!
Discover News you didn't know existed
Biologic Therapy
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Focus on Health
Published July 9, 2009, 6:25 pm, YourNabe.com
The documentation of the severity and risk for arthritis and the promise of biologic medications in treating major forms of arthritis are among the top 10 most significant arthritis advances of 2008, according to the Arthritis Foundation. The Arthritis Foundation’s annual top 10 list also includes clues to better understanding arthritis’ origins and the increase of government support for ...
My Pharmiweb.com
Published July 9, 2009, 2:34 am, PharmiWeb
Tokyo and Osaka, Japan - July 8, 2009 – Wyeth K.K. (Wyeth) and Takeda Pharmaceutical Company Limited (Takeda) announced that on July 7, 2009 Wyeth had received approval from the Japanese Ministry of Health, Labour and Welfare to add the indication of treating polyarticular Juvenile Idiopathic Arthritis (JIA) to “ENBREL 25mg for S.C. Injection,” (etanercept) which Wyeth and Takeda co-promote.
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
Published July 8, 2009, 5:15 am, Business Wire via Yahoo! Finance
FRAMINGHAM, Mass.----GTC Biotherapeutics, Inc. has obtained exclusive worldwide rights to the development and commercialization of recombinant human alpha-fetoprotein , including the recombinant, non-glycosylated version of rhAFP known as MM-093, for the treatment of autoimmune diseases from Merrimack Pharmaceuticals.
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
Published July 8, 2009, 3:57 am, redOrbit
SOUTH SAN FRANCISCO, Calif. and BOSTON, July 8 /PRNewswire/ -- iZumi Bio, Inc. and Pierian, Inc. today announced they have merged to form a new company, iPierian, Inc.
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
Published July 7, 2009, 11:02 pm, PR Newswire via Yahoo! Finance
iZumi Bio, Inc. and Pierian, Inc. today announced they have merged to form a new company, iPierian, Inc. Building on the iZumi infrastructure and vision, the company is focused on the application of cellular reprogramming to change the paradigm of drug discovery.
CEL-SCI Corporation Releases Letter to Shareholders
Published July 7, 2009, 6:45 am, PR Newswire via Yahoo! Finance
The following letter is being released by CEL-SCI Corporation to its shareholders:
Global Autoimmune Disease Therapeutics Market To Reach $50B By 2015, According To A New Report By Global Industry ...
Published July 3, 2009, 3:31 am, BioresearchOnline
Global market for Autoimmune Disease Therapeutics is projected to reach US$49.8B in 2015. Biologics emerged as the leading therapeutic option in the treatment of autoimmune diseases, owing to their superior efficacy compared to conventional small molecule drugs.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |